GGrantIndex
← Search

GV150526 IN TREATMENT OF ACUTE STROKE

$19,199M01FY2000RRNIH

Case Western Reserve University, Cleveland OH

Investigators

Linked publications & trials

Abstract

This is a multicenter randomized double-blind placebo controlled parallel group study evaluating the efficacy and safety of GC150526 or placebo in patients with a clinical diagnosis of acute stroke. This drug is a potent glycine antagonist. Glycine is a co-agonist of the NMDA receptor for glutamine-induced and neuroexcitation. Since this NMDA receptor by stimulation of this NMDA receptor by glutamate may be cytotoxic during cerebral ischemia, antagonism of this receptor may be beneficial.

View original record on NIH RePORTER →